Phase 3 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women between 18 and 75 years old (inclusive) who are able to understand, agree to, and sign the trial consent form.
• People who are generally able to carry out daily activities with little or no limitation (as measured by a standard medical scale called ECOG, with a score of 0 or 1).
• People who have been diagnosed with cervical cancer that has come back or spread, confirmed by tissue testing, and is of a specific type (squamous cell, HPV-associated adenocarcinoma, or adenosquamous), and where surgery or combined chemotherapy and radiation aimed at a cure are not suitable options.
• People who have previously received a platinum-based chemotherapy (with or without a drug called bevacizumab) and have had no more than 2 prior systemic treatments for recurrent or metastatic disease, and whose cancer has been shown on scans to have gotten worse during or after their last treatment.
• People who are able to provide either a stored tumour tissue sample or a fresh tissue sample.
• People with a life expectancy of at least 12 weeks.
• People whose cancer can be measured on scans according to a standard system called RECIST version 1.1.
• People whose health is considered adequate to receive one of the chemotherapy options used in the comparison group (gemcitabine, pemetrexed, or topotecan).
• People whose kidneys, liver, blood, and other organs are functioning at an adequate level.
• People who are sexually active and able to have children who agree to use contraception throughout the study and for at least 6 months after treatment ends.
• People who are willing to follow all study procedures.

Who may not be able to join:

• People whose cervical cancer is of a type not listed above, such as HPV-independent adenocarcinoma or primary neuroendocrine cervical cancer.
• People who have received chemotherapy or radiation within 21 days before the first study dose, certain traditional Chinese medicines with anti-cancer uses within 14 days, any experimental drug or device within 28 days, previous treatment with a specific type of targeted therapy called a nectin-4 ADC or an ADC containing MMAE, or certain strong medications that affect how the body processes drugs (CYP3A4 inhibitors) within 14 days before the first study dose.
• People who still have significant side effects (grade 2 or higher) from prior treatment, or who experienced serious immune-related side effects (grade 3 or higher) from previous immunotherapy.
• People who have a serious kidney obstruction (hydronephrosis) that cannot be managed with medical procedures, as assessed by the treating doctor.
• People who have had major surgery within 28 days before the first study dose.
• People whose blood sugar control marker (HbA1c) is 8% or higher.
• People who already have nerve damage in their hands or feet (peripheral neuropathy) at grade 2 or above.
• People who have received a live vaccine within 28 days before the first study dose or during the study.
• People with a documented history of a significant heart or stroke-related condition within 6 months before the first study dose.
• People with other serious or uncontrolled health conditions, such as severe breathing problems, blood clotting events, active bleeding, or active infection.
• People who have cancer that has spread to the brain or spinal fluid (central nervous system metastases).
• People who have had another cancer diagnosed within the past 3 years, unless that cancer has been fully cured.
• People who have been treated for an autoimmune disease with systemic (whole-body) medications within the past 2 years.
• People with certain existing eye conditions that may increase the risk of damage to the surface of the eye.
• People with a known allergy or sensitivity to any ingredient in the study drug, or a history of drug abuse or mental illness.
• People with uncontrolled cancer-related bone pain or pressure on the spinal cord.
• People with fluid build-up around the lungs, in the abdomen, or around the heart that is causing symptoms or requires draining.
• People in any situation or condition that the trial team determines would put them at significant risk.

Important: Always verify eligibility with the trial site directly before applying.